CD19 and Alzheimer disease: The increased proportions of SP-expressing CD4+, CD16+, and CD19+ leukocytes in the blood of AD patients is an interesting finding, but the fact that the MFI of CD4+, CD16+, and CD19+ leukocyte expression in the blood of AD patients was lower than that in HC blood remains unclear.